Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): A trial of the Eastern Cooperative Oncology Group Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Cyclosporins
  • Dexamethasone
  • Doxorubicin
  • Drug Resistance, Multiple
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Neoplasm Recurrence, Local
  • Vincristine

abstract

  • VAD plus PSC-833 had the same (21%) partial response rate as a prior ECOG study without PSC-833. No correlation of response with MDR or apoptosis testing was found. Other drug resistance factors must play a significant role in determining the response of relapsed patients with CLL.

publication date

  • August 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.leukres.2003.12.002

PubMed ID

  • 15203279

Additional Document Info

start page

  • 813

end page

  • 9

volume

  • 28

number

  • 8